Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US-10112920-B2 · Oct 30, 2018 · US
US9481639B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9481639-B2 |
| Application number | US-201313987655-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 19, 2013 |
| Priority date | Dec 21, 2006 |
| Publication date | Nov 1, 2016 |
| Grant date | Nov 1, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
Opening claim text (preview).
The invention claimed is: 1. A method for treating a subject suffering from acne, comprising administering to the subject an effective amount of a substituted tetracycline compound that is or a pharmaceutically acceptable salt thereof. 2. A method for treating a subject suffering from rosacea, comprising administering to the subject an effective amount of a substituted tetracycline compound that is or a pharmaceutically acceptable salt thereof. 3. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.01 to 100 milligrams per kilogram of body weight of the subject. 4. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.01 to 100 milligrams per kilogram of body weight of the subject. 5. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.1 to 50 milligrams per kilogram of body weight of the subject. 6. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 0.1 to 50 milligrams per kilogram of body weight of the subject. 7. The method according to claim 1 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 1 to 20 milligrams per kilogram of body weight of the subject. 8. The method according to claim 2 , wherein the amount of substituted tetracycline compound administered to the subject is in a range of from 1 to 20 milligrams per kilogram of body weight of the subject. 9. The method according to claim 1 , wherein the subject is a human. 10. The method according to claim 2 , wherein the subject is a human.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Anti-acne agents · CPC title
Antipsoriatics · CPC title
Drugs for dermatological disorders · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.